While the diagnostic and prognostic utility of CTCs in the general population must be assessed through larger prospective studies, our results support the use of DAPI+/E&M+/CD45-/HE4+ CTC counts for diagnosing ovarian cancer in patients with suspicious pelvic or abdominal masses. The gene discussed is WFDC2; the disease is ovarian cancer.